TABLE OF CONTENTS
1 INTRODUCTION 34
1.1 OBJECTIVES OF THE STUDY 34
1.2 MARKET DEFINITION 34
1.3 OVERVIEW OF THE GLOBAL FIBROTIC DISEASES TREATMENT MARKET 34
1.4 LIMITATIONS 36
1.5 MARKETS COVERED 36
2 MARKET SEGMENTATION 38
2.1 MARKETS COVERED 38
2.2 GEOGRAPHICAL SCOPE 39
2.3 YEARS CONSIDERED FOR THE STUDY 40
2.4 CURRENCY AND PRICING 40
2.5 DBMR TRIPOD DATA VALIDATION MODEL 41
2.6 MULTIVARIATE MODELLING 44
2.7 TREATMENT TYPE LIFELINE CURVE 44
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 45
2.9 DBMR MARKET POSITION GRID 46
2.10 MARKET END USER COVERAGE GRID 47
2.11 VENDOR SHARE ANALYSIS 48
2.12 SECONDARY SOURCES 49
2.13 ASSUMPTIONS 49
3 EXECUTIVE SUMMARY 50
4 PREMIUM INSIGHTS 52
4.1 PORTER'S 5 FORCES 55
4.2 PESTEL ANALYSIS 56
5 EPIDEMIOLOGY 57
5.1 INCIDENCE OF ALL BY GENDER 57
5.2 TREATMENT RATE 57
5.3 MORTALITY RATE 57
5.4 DRUG ADHERENCE AND THERAPY SWITCH MODEL 58
5.5 PATIENT TREATMENT SUCCESS RATE 58
6 INDUSTRY INSIGHTS 59
6.1 PATENT ANALYSIS 59
6.2 DRUG TREATMENT RATE BY MATURED MARKETS 59
6.3 DEMOGRAPHIC TRENDS: IMPACTS ON ALL INCIDENCE RATE 59
6.4 KEY PRICING STRATEGIES 60
6.5 KEY PATIENT ENROLLMENT STRATEGIES 61
7 MERGERS AND ACQUISITIONS 63
7.1 LICENSING: 63
7.2 COMMERCIALIZATION AGREEMENTS 63
8 PIPELINE ANALYSIS 64
8.1 PHASE 1 64
8.2 PHASE 2 64
8.3 PHASE 3 64
9 GLOBAL FIBROTIC DISEASES TREATMENT MARKET, REGULATIONS 65
9.1 FDA APPROVALS 65
9.2 EMA APPROVALS 66
10 MARKET OVERVIEW 67
10.1 DRIVERS 69
10.1.1 RISING PREVALENCE OF FIBROTIC DISEASES 69
10.1.2 INCREASE IN THE NUMBER OF PEOPLE SMOKING CIGARETTES 69
10.1.3 TECHNOLOGICAL ADVANCEMENT IN THE TREATMENT OF FIBROSIS DISEASES 70
10.2 RESTRAINTS 70
10.2.1 HIGH COST OF MEDICATION AND TREATMENTS 70
10.2.2 LACK OF EFFECTIVE BIOMARKERS AND DIAGNOSTIC TOOLS FOR EARLY DETECTION AND MONITORING OF FIBROTIC DISEASES 70
10.3 OPPORTUNITIES 71
10.3.1 RISING RESEARCH AND DEVELOPMENT ACTIVITIES 71
10.3.2 DEVELOPMENT OF NEW AND MORE EFFECTIVE THERAPIES FOR FIBROTIC DISEASES 71
10.4 CHALLENGES 72
10.4.1 THE COMPLEX AND MULTIFACTORIAL NATURE OF FIBROTIC DISEASES. 72
10.4.2 HIGH RATE OF FAILURE IN CLINICAL TRIALS FOR FIBROTIC DISEASES, WHICH CAN RESULT IN SIGNIFICANT COSTS AND DELAYS IN DRUG DEVELOPMENT 72
11 GLOBAL FIBROTIC DISEASES TREATMENT MARKET: BY TREATMENT 73
11.1 OVERVIEW 74
11.2 MEDICATION 76
11.2.1 INTEDANIB (OFEV) 77
11.2.2 PIRFENIDONE (ESBRIET) 77
11.3 ORGAN TRANSPLANTATION 77
11.4 OXYGEN THERAPY 78
11.5 OTHERS 79
12 GLOBAL FIBROTIC DISEASES TREATMENT MARKET, BY APPLICATION 80
12.1 OVERVIEW 81
12.2 IDIOPATHIC PULMONARY FIBROSIS 84
12.3 HEPATIC CIRRHOSIS 84
12.4 RENAL FIBROSIS 85
12.5 CUTANEOUS FIBROSIS 86
12.6 OTHERS 87
13 GLOBAL FIBROTIC DISEASES TREATMENT MARKET, BY END USER 88
13.1 OVERVIEW 89
13.2 HOSPITALS 92
13.3 SPECIALTY CLINICS 93
13.4 ACADEMIC AND RESEARCH INSTITUTES 93
13.5 OTHERS 94
14 GLOBAL FIBROTIC DISEASES TREATMENT MARKET, BY DISTRIBUTION CHANNEL 95
14.1 OVERVIEW 96
14.2 HOSPITAL PHARMACY 99
14.3 RETAIL PHARMACY 99
14.4 OTHERS 100
15 GLOBAL FIBROTIC DISEASES TREATMENT MARKET, BY REGION 101
15.1 OVERVIEW 102
15.2 NORTH AMERICA 107
15.2.1 U.S. 113
15.2.2 CANADA 115
15.2.3 MEXICO 117
15.2.4 DOMINICAN REPUBLIC 119
15.2.5 JAMAICA 121
15.2.6 PANAMA 123
15.3 EUROPE 125
15.3.1 GERMANY 132
15.3.2 FRANCE 134
15.3.3 U.K. 136
15.3.4 ITALY 138
15.3.5 SPAIN 140
15.3.6 RUSSIA 142
15.3.7 TURKEY 144
15.3.8 NETHERLANDS 146
15.3.9 SWITZERLAND 148
15.3.10 HUNGARY 150
15.3.11 LITHUANIA 152
15.3.12 AUSTRIA 154
15.3.13 IRELAND 156
15.3.14 NORWAY 158
15.3.15 POLAND 160
15.3.16 REST OF EUROPE 162
15.4 ASIA-PACIFIC 163
15.4.1 JAPAN 170
15.4.2 CHINA 172
15.4.3 INDIA 174
15.4.4 SOUTH KOREA 176
15.4.5 AUSTRALIA 178
15.4.6 SINGAPORE 180
15.4.7 THAILAND 182
15.4.8 MALAYSIA 184
15.4.9 INDONESIA 186
15.4.10 PHILIPPINES 188
15.4.11 VIETNAM 190
15.4.12 TAIWAN 192
15.4.13 REST OF ASIA-PACIFIC 194
15.5 SOUTH AMERICA 195
15.5.1 BRAZIL 202
15.5.2 ECUADOR 204
15.5.3 CHILE 206
15.5.4 COLUMBIA 208
15.5.5 VENEZUELA 210
15.5.6 ARGENTINA 212
15.5.7 PERU 214
15.5.8 CURACAO 216
15.5.9 PARAGUAY 218
15.5.10 URUGUAY 220
15.5.11 TRINIDAD AND TOBAGO 222
15.5.12 REST OF SOUTH AMERICA 224
15.6 MIDDLE EAST AND AFRICA 225
15.6.1 SOUTH AFRICA 231
15.6.2 SAUDI ARABIA 233
15.6.3 U.A.E 235
15.6.4 EGYPT 237
15.6.5 KUWAIT 239
15.6.6 ISRAEL 241
15.6.7 BAHRAIN 243
15.6.8 REST OF MIDDLE EAST AND AFRICA 245
16 GLOBAL FIBROTIC DISEASES TREATMENT MARKET, COMPANY LANDSCAPE 246
16.1 COMPANY SHARE ANALYSIS: GLOBAL 246
16.2 COMPANY SHARE ANALYSIS: NORTH AMERICA 247
16.3 COMPANY SHARE ANALYSIS: EUROPE 248
16.4 COMPANY SHARE ANALYSIS: ASIA-PACIFIC 249
17 SWOT ANALYSIS 250
18 COMPANY PROFILE 251
18.1 BOEHRINGER INGELHEIM INTERNATIONAL GMBH 251
18.1.1 COMPANY SNAPSHOT 251
18.1.2 REVENUE ANALYSIS 251
18.1.3 COMPANY SHARE ANALYSIS 252
18.1.4 PRODUCT PORTFOLIO 252
18.1.5 RECENT DEVELOPMENTS 252
18.2 GENENTECH, INC. 253
18.2.1 COMPANY SNAPSHOT 253
18.2.2 COMPANY SHARE ANALYSIS 253
18.2.3 PRODUCT PORTFOLIO 254
18.2.4 RECENT DEVELOPMENTS 254
18.3 SANDOZ INTERNATIONAL GMBH 255
18.3.1 COMPANY SNAPSHOT 255
18.3.2 COMPANY SHARE ANALYSIS 255
18.3.3 PRODUCT PORTFOLIO 256
18.3.4 RECENT DEVELOPMENTS 256
18.4 TEVA PHARMACEUTICAL INDUSTRIES LTD. 257
18.4.1 COMPANY SNAPSHOT 257
18.4.2 REVENUE ANALYSIS 257
18.4.3 COMPANY SHARE ANALYSIS 258
18.4.4 PRODUCT PORTFOLIO 258
18.4.5 RECENT DEVELOPMENTS 258
18.5 ACCORD HEALTHCARE U.S. 259
18.5.1 COMPANY SNAPSHOT 259
18.5.2 COMPANY SHARE ANALYSIS 259
18.5.3 PRODUCT PORTFOLIO 260
18.5.4 RECENT DEVELOPMENTS 260
18.6 ABBVIE INC. 261
18.6.1 COMPANY SNAPSHOT 261
18.6.2 REVENUE ANALYSIS 261
18.6.3 PRODUCT PORTFOLIO 262
18.6.4 RECENT DEVELOPMENTS 262
18.7 ALPINE IMMUNE SCIENCES 263
18.7.1 COMPANY SNAPSHOT 263
18.7.2 REVENUE ANALYSIS 263
18.7.3 PRODUCT PORTFOLIO 264
18.7.4 RECENT DEVELOPMENTS 264
18.8 BELLBROOK LABS 265
18.8.1 COMPANY SNAPSHOT 265
18.8.2 PRODUCT PORTFOLIO 265
18.8.3 RECENT DEVELOPMENTS 265
18.9 BIOMX 266
18.9.1 COMPANY SNAPSHOT 266
18.9.2 REVENUE ANALYSIS 266
18.9.3 PRODUCT PORTFOLIO 267
18.9.4 RECENT DEVELOPMENTS 267
18.10 BRISTOL-MYERS SQUIBB COMPANY 268
18.10.1 COMPANY SNAPSHOT 268
18.10.2 REVENUE ANALYSIS 268
18.10.3 PRODUCT PORTFOLIO 269
18.10.4 RECENT DEVELOPMENTS 269
18.11 CAMBER PHARMACEUTICALS, INC. 270
18.11.1 COMPANY SNAPSHOT 270
18.11.2 PRODUCT PORTFOLIO 270
18.11.3 RECENT DEVELOPMENTS 270
18.12 ENVEDA 271
18.12.1 COMPANY SNAPSHOT 271
18.12.2 PRODUCT PORTFOLIO 271
18.12.3 RECENT DEVELOPMENTS 271
18.13 GILEAD SCIENCES, INC. 272
18.13.1 COMPANY SNAPSHOT 272
18.13.2 REVENUE ANALYSIS 272
18.13.3 PRODUCT PORTFOLIO 273
18.13.4 RECENT DEVELOPMENTS 273
18.14 INTERCEPT PHARMACEUTICALS, INC. 274
18.14.1 COMPANY SNAPSHOT 274
18.14.2 REVENUE ANALYSIS 274
18.14.3 PRODUCT PORTFOLIO 275
18.14.4 RECENT DEVELOPMENTS 275
18.15 KITHER BIOTECH S.R.L. 276
18.15.1 COMPANY SNAPSHOT 276
18.15.2 PRODUCT PORTFOLIO 276
18.15.3 RECENT DEVELOPMENTS 276
18.16 PHARMAXIS LTD 277
18.16.1 COMPANY SNAPSHOT 277
18.16.2 REVENUE ANALYSIS 277
18.16.3 PRODUCT PORTFOLIO 278
18.16.4 RECENT DEVELOPMENTS 278
18.17 REDX PHARMA PLC. 279
18.17.1 COMPANY SNAPSHOT 279
18.17.2 REVENUE ANALYSIS 279
18.17.3 PRODUCT PORTFOLIO 280
18.17.4 RECENT DEVELOPMENTS 280
18.18 VERONA PHARMA PLC 281
18.18.1 COMPANY SNAPSHOT 281
18.18.2 REVENUE ANALYSIS 281
18.18.3 PRODUCT PORTFOLIO 282
18.18.4 RECENT DEVELOPMENTS 282
19 QUESTIONNAIRE 283
20 RELATED REPORTS 286

Menu 2

Sed ut perspiciatis unde omnis iste natus error sit voluptatem accusantium doloremque laudantium, totam rem aperiam.